¾à¹°À¯ÀüüÇÐ ½ÃÀå º¸°í¼­ : ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)
Pharmacogenomics Market Report by Technology, Application, End User, and Region 2024-2032
»óǰÄÚµå : 1561455
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 136 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,255,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,674,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,094,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 79¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº ÇâÈÄ ½ÃÀåÀÌ 2032³â±îÁö 161¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, 2024³âºÎÅÍ 2032³â±îÁö 7.9%ÀÇ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

¾à¹°À¯ÀüüÇÐÀº ƯÁ¤ ¾à¹°¿¡ ´ëÇÑ Àΰ£ À¯ÀüÀÚÀÇ À¯ÀüÀû µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ ¿¬±¸ÀÔ´Ï´Ù. ¾à¸®Çаú À¯ÀüüÇÐÀÇ ¿ø¸®¸¦ ÀÌ¿ëÇÏ¿© °³ÀÎÀÇ À¯ÀüÀÚ ±¸¼º¿¡ ¸Â´Â È¿°úÀûÀÌ°í ¾ÈÀüÇÑ ÀǾàǰÀ» °³¹ßÇÕ´Ï´Ù. ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR), ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, µ¥¿Á½Ã¸®º¸ ÇÙ»ê(DNA) ½ÃÄö½Ì, Áú·® ºÐ¼®, Àü±â¿µµ¿ µî ´Ù¾çÇÑ ±â¼úÀÌ »ç¿ëµË´Ï´Ù. ¾à¹°À¯ÀüüÇп¡¼­ ¼öÇàµÈ À¯ÀüÀÚ °Ë»ç´Â ƯÁ¤ Áúº´¿¡ ´ëÇÑ °¨¼ö¼º ¹× »õ·Î °³¹ßµÈ ¾à¹°ÀÇ È¿´ÉÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¾à¹°À¯ÀüüÇд ½ÉÇ÷°ü, ¾ËÃ÷ÇÏÀ̸Ó, ¾Ï, Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º, ÈÄõ¼º ¸é¿ª °áÇÌ ÁõÈıº(HIV/AIDS), õ½Ä µî ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡µµ ³Î¸® ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù.

¾à¹°À¯ÀüüÇÐ ½ÃÀå µ¿Çâ :

¼¼°è Á¦¾à ¾÷°èÀÇ ÇöÀúÇÑ ¼ºÀåÀº ½ÃÀåÀÇ ¹àÀº Àü¸ÁÀ» âÃâÇÏ´Â Áß¿äÇÑ ¿ä¼Ò Áß ÇϳªÀÔ´Ï´Ù. °Ô´Ù°¡ ÀǾàǰÀÇ ¾ÈÀü¼ºÀ» ³ôÀÎ Á¤¹Ð ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÀûÀÎ »ýȰ½À°üº´ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϰí È¿´ÉÀ» Çâ»ó½ÃŲ Ç¥Àû ¾à¹°¿ä¹ýÀÇ Ã¤¿ëÀÌ È®»êµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¾à¹°À¯ÀüüÇд ¾Ï Ä¡·á¿¡µµ ³Î¸® ÀÌ¿ëµÇ¾î È­Çпä¹ý¾àÀ̳ª Ç¥Àû ¸é¿ª»ý¹°ÇÐÀû Á¦Á¦ÀÇ ¾à¹°¹ÝÀÀ, ³»¼º, È¿´É, µ¶¼ºÀÇ °¡´É¼ºÀ» ¿¹ÃøÇÔÀ¸·Î½á ½ÃÀå ¼ºÀå¿¡ ¶ÇÇÑ ±â¿©ÇÕ´Ï´Ù. ¶ÇÇÑ, ¾à¸® À¯Àüü ¹ÙÀÌ¿À¸¶Ä¿ Ç¥Áö ¼Ö·ç¼ÇÀÇ °³¹ß µî ´Ù¾çÇÑ ±â¼úÀû Áøº¸µµ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. À̵éÀº ½Åü¿¡¼­ ȸÇÇ °¡´ÉÇÑ ¾à¹° À¯ÇØ ¹ÝÀÀ(ADR)ÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­Çϰí ÀÓ»ó °á°ú¸¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ±âŸ ¿äÀÎÀ¸·Î´Â ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿, ÇコÄɾî ÀÎÇÁ¶óÀÇ ´ëÆøÀûÀÎ °³¼± µîÀ» µé ¼ö ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­¹®

Á¦5Àå ¼¼°èÀÇ ¾à¹°À¯ÀüüÇÐ ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : ±â¼úº°

Á¦7Àå ½ÃÀå ³»¿ª : ¿ëµµº°

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦10Àå SWOT ºÐ¼®

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global pharmacogenomics market size reached US$ 7.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 16.1 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032.

Pharmacogenomics is the study of inherited variations in human genes in response to specific drugs. It utilizes the principles of pharmacology and genomics to develop effective and safe medications that are customized to the genetic makeup of an individual. It involves the use of various technologies, such as polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry and electrophoresis. The genetic tests performed in pharmacogenomics aid in determining the susceptibility to certain diseases and efficacy of the newly developed drugs. Pharmacogenomics is also widely used in the treatment of various diseases, such as cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) and asthma.

Pharmacogenomics Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing demand for precision medicines with enhanced drug safety is providing a thrust to the growth of the market. With the increasing prevalence of chronic lifestyle diseases, there is widespread adoption of targeted drug therapies with minimal side effects and improved efficacy. In line with this, pharmacogenomics is also extensively used for cancer treatments and anticipating the possible drug responses, resistance, efficacy and toxicity of the chemotherapeutic and targeted immune biologic agents, which is also contributing to the market growth. Additionally, various technological advancements, such as the development of pharmacogenomic biomarker labeling solutions, are acting as other growth-inducing factors. They aid in minimizing the risks of avoidable adverse drug reactions (ADRs) in the body and improve clinical outcomes. Other factors, including extensive research and development (R&D) activities, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmacogenomics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on technology, application and end user.

Breakup by Technology:

Breakup by Application:

Breakup by End User:

Breakup by Region:

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Pharmacogenomics Market

6 Market Breakup by Technology

7 Market Breakup by Application

8 Market Breakup by End User

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â